PTSD patients get extended relief: methylone study shows promise for Long-Term control

NCT ID NCT06237426

Completed Disease control Sponsor: Transcend Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 44 people with PTSD who had already completed a prior methylone (TSND-201) trial. Over 52 weeks, researchers checked their symptoms and safety each month. If PTSD symptoms returned, participants could receive more methylone treatment. The goal was to see if the drug can safely manage PTSD over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-TRAUMATIC STRESS DISORDER

Contacts and locations

Show contact details

Locations

Cambridgeshire and Peterborough NHS Foundation Trust

Cambridge, England, United Kingdom
Cedar Clinical Research, Inc

Draper, Utah, 84020, United States
Clerkenwell Health

London, United Kingdom
Kings College

London, United Kingdom
La Nua Mental Health Centre

Galway, Ireland
Mirabilis Health

Belfast, Northern Ireland, United Kingdom
Mountain View Clinical Research

Denver, Colorado, 80209, United States
NHS Greater Glasgow and Clyde

Glasgow, Scotland, United Kingdom
Sunstone Medical

Rockville, Maryland, 20850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.